Healthcare Finance >>>

    Celgene’s Abraxane May Add Lung Cancer Use

    Celgene’s Abraxane may receive FDA approval for lung cancer by Oct. 12. The company applied for approval of the drug in combination with carboplatin as a treatment for first-line non-small cell lung cancer (NSCLC) patients who are not candidates for potentially curative surgery and/or radiation therapy. Read more>>

    Novo Nordisk, Sanofi, GSK Present Diabetes Data

    The European Association for the Study of Diabetes (EASD) annual meeting will take place in Berlin on Oct. 1-5. Novo Nordisk will present data from the Phase III program of its basal insulin Tresiba that is under FDA and European regulatory review for type I and type II diabetes. Read more>>

    Roche, Synta, Ariad Present Cancer Drug Data

    The 2012 European Society for Medical Oncology (ESMO) Congress takes place this week in Vienna from Sept. 28 to Oct. 2. Roche will present data from a Phase III trial called Hera on Oct. 1 that may show the length of use of Herceptin in the adjuvant setting in HER2-positive breast cancer can be doubled. Herceptin, [...]

    Regeneron Eylea May See Second Eye Approval

    Regeneron’s Eylea may receive FDA approval for a second use on Sept. 23 that would further expand the commercial opportunity for the company. The drug, which is already approved for neovascular age-related macular degeneration (wet AMD) is under review for use in central retinal vein occlusion (CRVO). In wet AMD, Eylea competes with Roche/Novartis’ Lucentis and [...]

    Hospitals’ Bad Debt Expenses Rise as Uninsured Grow

    FDA Approved Most Generics in August in 2012

    Healthcare Finance Audio Series

    CEO David Pyott Says Allergan Will Continue to Invest in Ophthalmology, New Uses of Botox Take a free trial to Healthcare Finance here

    Marc Cabrera Sees Continued Middle-Market Healthcare Consolidation in 2012

    Marc Cabrera, head of healthcare investment at Morgan Joseph TriArtisan, said continued consolidation across all subsectors of healthcare can be expected for the remainder of the year, in an interview with Elizabeth Krutoholow. He expects the majority of activity will be middle market deals with high premiums for the best companies. Q: How would you [...]

    Gilead’s Quad May Eventually Face Competition From GSK, Pfizer and Shionogi’s Single Pill

    Gilead is looking to maintain its dominance in the HIV market with the introduction of a once-daily complete single tablet regimen for HIV infection called Quad. Quad would be the first single tablet containing an integrase inhibitor if it is approved for marketing in the U.S. The company could eventually see competition from Viiv (a [...]

    Glaxo’s Advair May Face Larger Than Forecasted Generic Hit

    Sales of GlaxoSmithKline’s (Glaxo) Advair may decline significantly if generic drugmakers Mylan, Sandoz and Vectura are able to convince U.S. regulators to approve a truely substitutable generic. Generic manufacturers have gained approval for the drug, but not the delivery technology. Mylan is working on a substitutable Advair that includes both the inhalation technology in the device as well as the [...]

Bloomberg BRIEF Newsletters